This site is intended for healthcare professionals

Sanofi and GSK initiate global phase III clinical efficacy study of COVID-19 vaccine candidate.

Read time: 1 mins
Last updated:28th Jun 2021
Published:28th May 2021
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase III clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest